Correction: Kaletra price in South Africa

16 March 2005

This article is more than 19 years old. Click here for more recent articles on this topic

A news story published on March 14 (South Africa awards antiretroviral supply contracts) contained an error regarding the price of Kaletra. Abbott Laboratories has asked us to point out that the price of Kaletra (lopinavir/ritonavir) in South Africa will remain fixed at $500 throughout the period of the contract and will not increase by 32% over two years, as originally stated in Business Day on March 4, 2005.

Correction: Kaletra price in South Africa

Caution advised when prescribing long-acting injectable cabotegravir and rilpivirine to avoid drug resistance

Dissent on doxyPEP: recent guidelines becoming more cautious

Switching from TAF to TDF leads to weight loss

More evidence that PrEP works as well for women

Adolescent mothers with HIV in South Africa have poorer HIV outcomes than non-mothers, study finds

FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV

Still no cure for HIV and Aids yet – not even ‘gene therapy’

Small Study Finds No Need for Double-Dosing Dolutegravir After Switching From Failing Efavirenz-Based Regimen

Widely used HIV drug in South Africa flagged for reports of resistance – but experts say don’t panic

Health Equity Must Be “The Center of All That We Do” to Reduce Racial/Ethnic Disparities in HIV